Delving into the Latest Updates on Yaotang (Nanjing) Biotechnology Co., Ltd. with Synapse

Overview

Tags

Congenital Disorders

Endocrinology and Metabolic Disease

Nervous System Diseases

mRNA

Transformer Base Editor

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	2
Nervous System Diseases	1

Top 5 Drug Type	Count

mRNA	1
Transformer Base Editor	1

Top 5 Target	Count

PCSK9(Proprotein convertase subtilisin kexin type 9)	1
TTR(Transthyretin)	1

主要目的：评价在HeFH患者中给予SAL061后的安全性和耐受性；次要目的：（1）评价在HeFH患者中给予SAL061后的药代动力学特征；（2）评价在HeFH患者中给予SAL061后的药效学特征；（3）评价在HeFH患者中给予SAL061后的初步有效性；（4）评价在HeFH患者中给予SAL061后的免疫原性。

[Translation]

Primary objectives: To evaluate the safety and tolerability of SAL061 in HeFH patients; Secondary objectives: (1) To evaluate the pharmacokinetic characteristics of SAL061 in HeFH patients; (2) To evaluate the pharmacodynamic characteristics of SAL061 in HeFH patients; (3) To evaluate the preliminary efficacy of SAL061 in HeFH patients; (4) To evaluate the immunogenicity of SAL061 in HeFH patients.

Start Date13 Nov 2025

Sponsor / Collaborator

Shenzhen Salubris Pharmaceuticals Co., Ltd.

[+1]

CTR20241309

/ Not yet recruitingPhase 1

评价 YOLT-201 在转甲状腺素蛋白淀粉样变性多发性神经病（ATTR-PN）和转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）患者中的安全性、耐受性、药代动力学及药效学的开放、单次给药、剂量递增及剂量扩展的 I/IIa 期临床研究

[Translation] Phase I/IIa open-label, single-dose, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of YOLT-201 in patients with transthyretin amyloid polyneuropathy (ATTR-PN) and transthyretin amyloid cardiomyopathy (ATTR-CM)

主要目的：评价在 ATTR-PN 和 ATTR-CM 患者中给予 YOLT-201 后的安全性和耐受性；次要目的：（1）评价在ATTR-PN和ATTR-CM患者中给予YOLT-201后的药代动力学特征；（2）评价在ATTR-PN和ATTR-CM患者中给予YOLT-201后的药效学特征；（3）评价在ATTR-PN和ATTR-CM患者中给予YOLT-201后的初步有效性；（4）评价在ATTR-PN和ATTR-CM患者中给予YOLT-201后的免疫原性。探索性目的：评价在ATTR-CM患者中给予YOLT-201后的99Tcm-PYP摄取

[Translation]

Primary objectives: To evaluate the safety and tolerability of YOLT-201 in patients with ATTR-PN and ATTR-CM; Secondary objectives: (1) To evaluate the pharmacokinetic characteristics of YOLT-201 in patients with ATTR-PN and ATTR-CM; (2) To evaluate the pharmacodynamic characteristics of YOLT-201 in patients with ATTR-PN and ATTR-CM; (3) To evaluate the preliminary efficacy of YOLT-201 in patients with ATTR-PN and ATTR-CM; (4) To evaluate the immunogenicity of YOLT-201 in patients with ATTR-PN and ATTR-CM. Exploratory objectives: To evaluate the uptake of 99Tcm-PYP in patients with ATTR-CM after YOLT-201 administration

Start Date-

Sponsor / Collaborator

Yaotang (Nanjing) Biotechnology Co., Ltd.

100 Clinical Results associated with Yaotang (Nanjing) Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Yaotang (Nanjing) Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Yaotang (Nanjing) Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Yaotang (Nanjing) Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

YOLT-201 ( TTR )	Transthyretin-related (ATTR) familial amyloid polyneuropathy More	Phase 1
YOLT-101 ( PCSK9 )	Heterozygous familial hypercholesterolemia More	Phase 1